glp-1 receptor agonists effects on cardiovascular risk reduction and outcome trials: An update Discover the Game-Changing Benefits of

Does the answer depend on preexisting patient-related factors that we are unaware of as of now

When a patient's blood sugar levels are high, GLP-1 drugs send signals to their pancreas to secrete more insulin but the hormone-mimicking doesn't stop there

European Heart Journal - Cardiovascular Pharmacotherapy 10(4):296306 Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

That year 390 million children and adolescents aged 5-19 were thought to be overweight, of whom 160 million were obese (WHO 2024)

However, these types of bariatric surgery are very invasive and involve an irreversible manipulation of the gastrointestinal tract (reviewed in Stefater et al., 2012)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia